Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.39 |
| ▸ | PDE4A | P27815 | 8/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18068012 | 0.94 | PDE10A (0.41) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21212780 | 0.89 | NOS3 (0.35) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12986697 | 0.84 | PDE10A (0.39) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20642371 | 0.84 | PDE10A (0.35) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25928397 | 0.82 | PDE10A (0.34) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20642389 | 0.80 | PDE10A (0.32) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21212746 | 0.80 | PDE10A (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22681226 | 0.77 | CHRNA7 (0.45) | CCNT1CDK9HRH4ALOX5APFEN1 | |
| SCHEMBL24750096 | 0.76 | PDE10A (0.33) | PDE10ACCNT1CDK9 | |
| SCHEMBL22550831 | 0.76 | PDE2A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | CHRM3 970/4885PDE4A 964/4885PDE4B 1222/4885 |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | TRPA1, TRPV1, TRPV5 | CHRM3 970/4885PDE4A 964/4885PDE4B 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.